Clinical Trial Update: A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of EGF816 (osimertinib) in combination with Gefitinib in TKI-naïve EGFR-mutant non-small cell lung cancer was terminated and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF816
• Gefitinib (Gefitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-06-10